Published in Trends Microbiol on March 04, 2011
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res (2014) 1.04
Inhibition of influenza H7 hemagglutinin-mediated entry. PLoS One (2013) 0.90
Characterization of influenza hemagglutinin interactions with receptor by NMR. PLoS One (2012) 0.90
Small ruminant lentivirus genetic subgroups associate with sheep TMEM154 genotypes. Vet Res (2013) 0.88
HIV-1 envelope protein gp41: an NMR study of dodecyl phosphocholine embedded gp41 reveals a dynamic prefusion intermediate conformation. Structure (2014) 0.86
Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells. Proteome Sci (2012) 0.85
Probing the HIV gp120 envelope glycoprotein conformation by NMR. J Biol Chem (2011) 0.83
Dissecting virus entry: replication-independent analysis of virus binding, internalization, and penetration using minimal complementation of β-galactosidase. PLoS One (2014) 0.82
Co-expression of foreign proteins tethered to HIV-1 envelope glycoprotein on the cell surface by introducing an intervening second membrane-spanning domain. PLoS One (2014) 0.80
HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]. PLoS One (2013) 0.79
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. Curr HIV Res (2016) 0.77
Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. J Biomol NMR (2016) 0.77
Mutagenesis studies of the H5 influenza hemagglutinin stem loop region. J Biol Chem (2014) 0.77
HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses (2013) 0.77
Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells. PLoS One (2013) 0.76
SARS-CoV heptad repeat 2 is a trimer of parallel helices. Protein Sci (2011) 0.76
Antiviral mode of action of bovine dialyzable leukocyte extract against human immunodeficiency virus type 1 infection. BMC Res Notes (2011) 0.76
The membrane proximal external regions of gp41 from HIV-1 strains HXB2 and JRFL have different sensitivities to alanine mutation. Biochemistry (2015) 0.76
Computational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 Inhibitor. PLoS One (2015) 0.75
Native structure of a retroviral envelope protein and its conformational change upon interaction with the target cell. J Struct Biol (2016) 0.75
Comparative proteomics reveals novel components at the plasma membrane of differentiated HepaRG cells and different distribution in hepatocyte- and biliary-like cells. PLoS One (2013) 0.75
Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Retrovirology (2014) 0.75
The CpG dinucleotide content of the HIV-1 envelope gene may predict disease progression. Sci Rep (2017) 0.75
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Viral membrane fusion. Nat Struct Mol Biol (2008) 8.54
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell (1998) 4.73
HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell (2009) 4.63
Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature (2006) 4.44
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J (1998) 3.77
Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol (1999) 3.72
Protein design of an HIV-1 entry inhibitor. Science (2001) 3.38
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity (2008) 3.01
V3: HIV's switch-hitter. AIDS Res Hum Retroviruses (2005) 3.00
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2008) 2.93
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A (2003) 2.92
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov (2004) 2.46
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem (1993) 2.40
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell (2010) 2.22
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog (2007) 2.14
Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol (2007) 2.07
Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol (2007) 1.90
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1998) 1.69
Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem (2002) 1.57
AIDS virus envelope spike structure. Curr Opin Struct Biol (2007) 1.54
Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry (2005) 1.52
Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol (2002) 1.46
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry (2007) 1.46
Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem (2001) 1.45
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J Virol (2003) 1.43
Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine (2009) 1.37
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog (2008) 1.29
The extracellular domain of immunodeficiency virus gp41 protein: expression in Escherichia coli, purification, and crystallization. Protein Sci (1997) 1.29
Novel targets for antiretroviral therapy: clinical progress to date. Drugs (2009) 1.25
Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol (1999) 1.24
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry (2009) 1.20
Role of the HIV gp120 conserved domain 1 in processing and viral entry. J Biol Chem (2008) 1.19
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry (2004) 1.16
Alanine scanning mutants of the HIV gp41 loop. J Biol Chem (2005) 1.15
Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. Virology (1996) 1.12
Role of the HIV gp120 conserved domain 5 in processing and viral entry. Biochemistry (2008) 1.11
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother (2010) 1.07
Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007) 1.05
The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem (2010) 1.05
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother (2009) 1.03
Monomer-trimer equilibrium of the ectodomain of SIV gp41: insight into the mechanism of peptide inhibition of HIV infection. Protein Sci (1999) 1.02
Alanine scanning mutagenesis of HIV-1 gp41 heptad repeat 1: insight into the gp120-gp41 interaction. Biochemistry (2010) 0.99
HIV/SIV glycoproteins: structure-function relationships. J Mol Biol (1997) 0.99
Inhibition of intracellular proteolytic processing of soluble proproteins by an engineered alpha 2-macroglobulin containing a furin recognition sequence in the bait region. Biochem J (1997) 0.96
The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci (2007) 0.95
Microbicides in the prevention of HIV infection: current status and future directions. Drugs (2010) 0.95
Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J Biol Chem (2004) 0.93
Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrob Agents Chemother (2007) 0.93
HIV coreceptors. J Membr Biol (1998) 0.92
Peptide mimic of the HIV envelope gp120-gp41 interface. J Mol Biol (2007) 0.90
CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother (2010) 0.90
Protein structures: Structures of desire. Nature (2009) 0.90
Twenty-five years of HIV/AIDS. Science (2006) 0.90
Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state. J Biol Chem (2006) 0.89
The antiviral protein cyanovirin-N: the current state of its production and applications. Appl Microbiol Biotechnol (2010) 0.89
Heterobiaryl human immunodeficiency virus entry inhibitors. J Med Chem (2009) 0.84
SIV gp41 binds to membranes both in the monomeric and trimeric states: consequences for the neuropathology and inhibition of HIV infection. J Mol Biol (2001) 0.84
Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis. Biochim Biophys Acta (2003) 0.81
ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation. Antimicrob Agents Chemother (2010) 0.81
Design and optimisation of potent gp120-CD4 inhibitors. Bioorg Med Chem Lett (2009) 0.76
Effects of L- and D-REKR amino acid-containing peptides on HIV and SIV envelope glycoprotein precursor maturation and HIV and SIV replication. Biochem J (2002) 0.76